Zielgruppe

Employees from development, production, quality control, quality assurance and drug regulatory affairs in the pharmaceutical and biopharmaceutical industry

Zielsetzung

The first part oft he workshop will present different strategy approaches to comply with the regulations for MAHs in regards of nitrosamine impurities in human drugs. The scond part is focused on the upcoming challenging topic of nitrosamine impurities in biological medicinal products. The third part is designed as panel discussion for an extensive experience exchange on all aspects of nitrosamine impurities between speakers and participants.